ProCE Banner Activity

Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies

Tool

An interactive decision support tool designed to help HCPs manage adverse events associated with BCL-2 inhibitors in the setting of hematologic malignancies.

Released: August 23, 2024

Expiration: August 22, 2025

Share

Faculty

Farrukh T. Awan

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Courtney DiNardo

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Daniel A. Pollyea

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Caitlin R. Rausch

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AbbVie Inc.

AbbVie Inc.

Disclosure

Primary Author

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh Awan, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotech, ADCT Therapeutics, AstraZeneca, Beigene, Bristol Myers Squibb, Cardinal Health, Caribou Biosciences, Celgene, Cellecter Bioscience, Dava Oncology, Epizyme, Genentech, Genmab, Gilead, Incyte, Janssen, Johnson and Johnson, Karyopharm, Loxo Oncology, MEI Pharma, Merck, Pharmacyclics, Verastem; researcher: AbbVie, Pharmacyclics.

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Daiichi Sankyo, GenMab, Gilead, GlaxoSmithKline, Loxo, Novartis, Rigel, Schrodinger, Servier.

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Daniel A. Pollyea, MD, MS: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Kura, Link, Magenta, Novartis, OncoVerity, Qihan, Rigel, Ryvu, Syros, Sumitomo, Zentalis.

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Caitlin R. Rausch, PharmD, BCOP, has no relevant financial relationships to disclose.